Cara Therapeutics submits marketing application in Japan for pruritus drug

Tvardi Therapeutics

28/09/2022 15:36

** Drugmaker Cara Therapeutics Inc's shares  CARA.O  rise
2.7% to $8.90
    ** Co says its partner Maruishi Pharmaceutical submits
marketing application in Japan for drug to treat pruritus, a
condition of itchy skin in patients undergoing hemodialysis 
 urn:newsml:reuters.com:*:nGNX8MrRM1
    ** The drug, difelikefalin, has already been approved in the
U.S., Canada, Singapore, Europe
    ** Hemodialysis is a process to purify blood of a person
suffering from chronic kidney disease  
    ** Including session gains, stock lost ~26% YTD 
 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))